Advanced Search

Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2014 June;66(3) > Minerva Ginecologica 2014 June;66(3):313-24



A Journal on Obstetrics and Gynecology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index

Frequency: Bi-Monthly

ISSN 0026-4784

Online ISSN 1827-1650


Minerva Ginecologica 2014 June;66(3):313-24


The putative role and use of DHEA and its association with the hormone replacement therapy

Prati A. 1, Santagni S. 1, Rattighieri E. 1, Campedelli A. 1, Ricchieri F. 1, Chierchia E. 1, Despini G. 1, Genazzani A. R. 2, Genazzani A. D. 1

1 Centro di Ginecologia Endocrinologica, Clinica Ostetrica e Ginecologica, Dipartimento di Scienze Mediche e Chirurgiche, Materno-Infantili e dell’Adulto, Università di Modena e Reggio Emilia, Modena, Italia;
2 Clinica Ostetrica e Ginecologica, Università di Pisa, Pisa, Italia

The putative role and use of dehydroepiandrosterone (DHEA) as replacement therapy for menopausal women has been under consideration during the latest years. DHEA is one of the main adrenal hormones that progressively reduces its plasmatic levels from the beginning of ageing. This phenomenon implies not only the reduction of the plasmatic androgens but also the decrease of a peculiar category of hormones, named neurosteroids, in particular one: allopregnanolone. This review aims to elucidate the peculiar aspects of DHEA administration and its putative use as substitutive/integrative hormonal treatment alone or in combination with the traditional hormone replacement therapy.

language: Italian


top of page